Inside Peptides Mastermind • HRT & Alzheimer’s Risk • SS-31 • Google Health Agent • Chief Longevity Officer
Issue 65: The front page of longevity medicine - curated by doctors, for doctors.
Hey Doc,
Last Saturday, hundreds of doctors joined in person and virtually from around the world - India, Ghana, Singapore, Japan, Italy, Mexico, the UK, and beyond - to spend a full day exploring peptides in longevity medicine.
This is a vision coming true: democratizing longevity medicine globally.
Doctors from every country can now access the most cutting-edge education in medicine, no matter where they are.
Most importantly, we’re building a global community of physicians, now united across more than 300 cities.
Your feedback and support were heartwarming. Thank you to all the Longevity Docs who attended and supported!
Dr. David Luu
Founder, Longevity Docs
www.longevitydocs.org
In this week newsletter:
Inside Longevity Docs: Peptides Mastermind
Buzz in the Chat: HRT & AD • SS-31 • pTau217 • GLP1s & thyroid
Research Radar: Inflammation and CVD • Google Health Agent
Longevity in the News: Chief Longevity Officer • The promise of longevity
Longevity Intelligence: Midi Health • Costco • Ultrahuman
Our team is hard at work, and I’m excited to share what’s happening behind the scenes across the Longevity Docs ecosystem.
Inside the Longevity Docs Peptide Mastermind
If you walked into that room, you could feel it, the curiosity, the energy, the collective intelligence. From biology to regulation, the debate was intense, deeply respectful, and often humbling. I will try to give you a sense of how it felt from the inside.
Top 5 key takeways from our faculty:
1️⃣ Natural ≠ Safe — Dr. Len Pastrana
Peptides may be derived from biology, but quality and dosing define safety.
Dr. Pastrana reminded us that chronobiological dosing (timing therapy with circadian rhythm) is the future.
Takeaway: It’s not what you take; it’s when and how.
2️⃣ Heal the Immune System First — Dr. Matt Cook
“The immune system governs musculoskeletal healing.”
That one line reframed regenerative medicine.
Takeaway: Peptides are immune-training tools, not just repair signals.
3️⃣ The Skin’s Secret Clock — Dr. Saranya Wyles
From the Mayo Clinic, Dr. Wyles showed that skin defends by day and repairs by night.
Takeaway: True skin longevity honors cellular time, not skincare trends.
4️⃣ Seasonal Medicine — Dr. Elizabeth Yurth
Dr. Yurth’s talk on photobiomodulation connected red light, mitochondria, and peptides into one unified model. She even mapped peptide timing by season: spring and fall for building, winter and summer for repair.
Takeaway: Healing is seasonal
5️⃣ The Mitochondrial Heart — Dr. Abid Hussein
Using SS-31, Dr. Hussein showed how we can preserve the heart’s energy factory, cardiolipin.
Takeaway: The next frontier of cardiology is mitochondrial, not mechanical.
6️⃣ Simplicity Wins — Dr. Neil Paulvin
Before stacking 20 peptides, he reminded us: start with FDA-approved foundations like tesamorelin, SS-31, or GLP-1s.
Takeaway: Compliance beats complexity every time.
More about gut health, regulatory and the debate in the replay
The Community
What made this mastermind unforgettable was the people. Physicians who had only met on WhatsApp finally sat side by side. Over coffee, dinner, and shared notes, friendships were formed and collaborations began.
Every conversation carried the same spirit: we’ve found our tribe!
We don’t host conferences, we building the leading community in longevity medicine.
Access the Digital Mastermind
If you missed it, you can still be part of it.
Experience 8+ hours of faculty classes, debate, and clinical pearls from the world’s leading longevity physicians.
No fluff, no travel: just pure, actionable peptides education.
Every week, the Longevity Docs WhatsApp group feels like a front-row seat to the future of medicine. Here’s what had doctors buzzing:
Hormone Therapy & Alzheimer’s Risk
Doctors scrutinized a recent abstract linking HRT timing to Alzheimer’s risk. The group criticized its methodological weaknesses (mixed RCT/observational data, WHI bias).
The consensus: modern, personalized bioidentical protocols (micronized progesterone, testosterone, DHEA, pregnenolone) differ profoundly from older WHI-style studies.
They reframed the narrative toward precision hormone replacement as neuroprotective, not harmful.
Takeaway:
→ Longevity physicians are reclaiming the HRT conversation, emphasizing context, methodology, and individualized care over outdated mass-media interpretations.
Biomarkers for Cognitive Decline
When and how to use ptau217 testing for Alzheimer’s risk prediction.
CJ outlined a detailed workflow (Quest AD Detect + ApoE, pre-test counseling, follow-up PET & neuropsych).
S. highlighted ethical implications—insurance discrimination and patient anxiety.
EY reframed amyloid as “not causative,” emphasizing neuroinflammation and plasmalogen protection.
Consensus: testing has value, but counseling and follow-up strategy are essential; biomarkers alone don’t define destiny.
Takeaway:
→ Longevity Docs balance advanced diagnostics with patient psychology and ethics, moving beyond binary disease models toward “empowered awareness.”
Peptide SS-31 (Elamipretide) Approved
The FDA granted accelerated approval to FORZINITY™ (elamipretide, a.k.a. SS-31) as the first treatment for Barth syndrome, for patients ≥30 kg. It’s a once-daily subcutaneous injection and the first mitochondria-targeted therapy approved in the U.S.
Why it matters to clinicians:
Endpoint: Approval based on improved knee-extensor muscle strength (intermediate endpoint); a confirmatory RCT is required.
Safety/Use: Common AEs were injection-site reactions; approved under priority review with a rare pediatric disease voucher issued to Stealth BioTherapeutics.
Big picture: Validates mitochondria as a druggable target and signals momentum for mitochondrial medicine impacting strength/function in ultra-rare disease.
GLP-1s and Thyroid/Hashimoto’s Disease
Discussion: Whether GLP-1 agonists (e.g., Mounjaro) improve autoimmune thyroiditis or exacerbate reflux.
S. raised dual hypotheses: metabolic vs inflammatory effects.
CJ and TF contributed data on GERD and Barrett’s esophagus, referencing real-world management insights.
The consensus: GLP-1s help via weight-loss and metabolic improvements; early reflux is transient; titration and lifestyle counseling remain key.
Takeaway:
→ This is the kind of multi-angle, literature-anchored, experience-based reasoning that defines longevity medicine in practice.
Peptides & Regenerative Therapies
Community anecdotes: ML’s son’s recovery with BPC-157, NMN, GHK-Cu, CBD; SM’s ankle recovery; RH’s ACL case.
TF called for formal RCTs despite widespread anecdotal success, highlighting a collective desire for evidence generation and standardization.
Repeated questions arose about sourcing reputable 503A/503B compounding pharmacies, signaling unmet operational needs.
Takeaway:
→ The peptide space is maturing from anecdote to organized clinical data, and Longevity Docs positions itself as the bridge between innovation and evidence.
Join 500+ Longevity Docs Across 50 Countries
Longevity Docs is a highly vetted, invitation-only community for physicians shaping the future of longevity medicine. Apply online and connect 1:1 with our team
Each week, I highlight a few studies that caught our eyes and could shape the future of longevity medicine.
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology
Screen hsCRP broadly (with LDL) in primary & secondary prevention to detect residual inflammatory risk.
Treat what you measure: intensify statins if hsCRP >2 mg/L; add low-dose colchicine (0.5 mg/d) for stable ASCVD (adjunct to lipid lowering).
Lifestyle is anti-inflammatory: Mediterranean/DASH diet, omega-3 fish, exercise, weight control, no smoking.
Pipeline: IL-6–pathway drugs in trials; imaging biomarkers promising but not for routine care yet. JACC
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study
In a large international cohort study of over 4 million patients with type 2 diabetes, initiating GLP-1 receptor agonists (GLP-1RAs) after metformin did not increase the risk of thyroid tumors or malignancy compared with SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas. Across analyses (intention-to-treat, on-treatment, and 1-year lag), hazard ratios were close to 1.0, showing no significant association. Diabetes Cares
Google personal health agent
Learn about our research prototype, an LLM-powered personal health agent that analyzes data from everyday wellness devices paired with health data, such as blood biomarkers, to offer evidence-based health insights and to provide a personalized coaching experience. Google
I comb through the mainstream headlines, handpick the most relevant longevity stories.
Chief Longevity Officers are coming to the C-Suite. What are they?
Chief Longevity Officers could quickly grow in popularity as working lives become less of a straight line and more of a zig-zag. Quartz
The promise of longevity: A future with more time — and more meaning
When I think about longevity, I don’t think about science labs or supplements. I think about my paternal grandparents — my baba and pap-pap. As a latchkey kid growing up in Midland, Pennsylvania, in the ‘80s and early ‘90s, I spent many afternoons at their house, which was two doors down from ours. Freethink
Unlocking the Secrets to Living to 100
Want to enjoy a long, healthy, and happy life? Just live like a centenarian. That’s the advice of Stacy Andersen, a behavioral neuroscientist at Boston University and co-director of the New England Centenarian Study, the largest study of centenarians and their families in the world. Time
Every week, I track the biggest moves in longevity: new funding rounds, partnerships, product launches, and key hires.
Costco to sell Ozempic and Wegovy at a large discount for people without insurance
At $499 a month, the deal will help expand access to Novo Nordisk’s weight loss drugs, but doctors say the hugely popular medications will still be out of reach for many who need them. NBC News
Midi Health Raises $50M Series C for Menopause Care Platform
The virtual menopause and perimenopause care company now serves 20,000 patients weekly, roughly double its patient base from January 2025. CEO Joanna Strober shared that the company has reached a $150 million revenue run rate, up from $60 million at the end of 2024. FemtechInsider
Ultrahuman Launches Vision Cloud and $99 Blood Test to Redefine Health Accessibility
Ultrahuman, the global health technology company behind the Ring AIR, has redefined health accessibility with the launch of Vision Cloud (the world’s first free, universal interpreter for health reports) and Blood Vision Essentials The $99 preventive blood test covers 60+ biomarkers across eight major health panels, including metabolism, cardiovascular health, and immunity. HITconsultant
Longevity Docs AI/Tech Mastermind
New York City & Virtual | January 17, 2026
Longevity Docs Summit Cannes
Cannes, France | June 10-11, 2026
Longevity Docs Around the World
Meet Dr. David Luu and team at the following events:
Riyadh · October 24–26 — Zenos Health Summit
New York · October 30 — Galien Patient Summit
Miami · November 12 — Longevity Docs Table
Novato · December 6-8 — Longevity Clinic Roundtable
Vegas · January 6-9 — CES
Conferences Calendar
Health Optimization Medicine Symposium: Boulder, October 17-18
Biomarkers of Aging: Boston, October 20-21, 2025
Eudemonia: Palm Beach, November 13-16
A4M: Las Vegas, December 12-13
Hormones Mastermind Replay
For the first time, get full online access to the entire event:
✔ 10 expert-led modules
✔ Real-world protocols and case studies
✔ On-demand viewing, anytime, anywhere
No fluff, no travel: just pure, actionable hormone and longevity education.
Replay Pass: $399
Why every doctor should be a longevity doctor.
The Movement
Longevity Docs is the world’s leading collective of physicians advancing longevity medicine through education, clinical research, advisory, and exclusive experiences. With over 500 members in 50+ countries, we’re building the global infrastructure for evidence-based, personalized longevity care.
Why “Longevity Docs”?
Because we believe longevity is not a specialty — it’s a human right.
The future of medicine is proactive, not reactive. It's interdisciplinary, not isolated. It’s collaborative, data-driven, and deeply human. And it starts with us — the physicians who dare to redefine what care looks like across the decades of a patient’s life.
“Longevity Docs” isn’t just a name. It’s a statement of purpose.
Our Ecosystem
Physician Network
A trusted global collective of longevity-focused doctors exchanging protocols, referrals, and real-world clinical outcomes.Education & Certification
Earn your Certified Longevity Physician™ designation through our advanced curriculum, live masterclasses, and continuous learning tracks.Decentralized Research
Lead or participate in multicenter clinical trials and patient registries, accelerating evidence generation for healthspan optimization.Strategic Advisory
We partner with vetted longevity companies, life-science, tech, and clinics to help them grow.Global Events & Experiences
Access exclusive gatherings like the NYC Mastermind and the Cannes Longevity Summit & Awards
Who It’s For
Doctors → Join the club, get certified, grow your practice
Health Systems → Implement clinical longevity programs
Brands & Startups → Validate products, find advisors, run trials
Investors → Gain early access to insights, doctors, and deal flow
We’re not just witnessing the transformation of longevity medicine we’re building it. Together.
Subscribe to the Longevity Docs Newsletter
Stay connected with the backstage of the Longevity Docs community, a network of over 500 physicians spanning 50 countries, united in our mission to democratize longevity medicine. Explore the latest in evidence-based longevity care, gain exclusive access to physician insights, and join us in shaping the future of this transformative field.
Newsletter Disclaimer: